AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The sale was disclosed in a filing with the SEC, which is available at this link.
Daniel Faga also recently made the following trade(s):
- On Friday, March 22nd, Daniel Faga sold 145,940 shares of AnaptysBio stock. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20.
- On Monday, January 8th, Daniel Faga sold 6,866 shares of AnaptysBio stock. The shares were sold at an average price of $21.81, for a total transaction of $149,747.46.
AnaptysBio Stock Performance
Shares of AnaptysBio stock opened at $21.38 on Thursday. The company has a market cap of $572.13 million, a P/E ratio of -3.52 and a beta of -0.28. AnaptysBio, Inc. has a one year low of $13.36 and a one year high of $27.50. The firm has a fifty day moving average of $24.00 and a two-hundred day moving average of $20.21.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on AnaptysBio
Hedge Funds Weigh In On AnaptysBio
A number of large investors have recently bought and sold shares of ANAB. Quantbot Technologies LP purchased a new position in shares of AnaptysBio in the 2nd quarter valued at about $34,000. Tower Research Capital LLC TRC increased its holdings in shares of AnaptysBio by 248.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 2,565 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of AnaptysBio by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 2,390 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of AnaptysBio by 75.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 2,142 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of AnaptysBio by 134.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 3,381 shares in the last quarter.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Recommended Stories
- Five stocks we like better than AnaptysBio
- Investing in the High PE Growth Stocks
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- P/E Ratio Calculation: How to Assess Stocks
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.